The collaboration targets potential new therapeutics directed at microbiome targets thought to play crucial roles in gastrointestinal disorders, such as inflammatory bowel diseases (e.g. ulcerative colitis) and motility disorders (e.g. irritable bowel syndrome). Enterome Bioscience has developed a proprietary metagenomic platform of the microbiome.
Takeda news release, January 6, 2016